Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | The Indian Pharmaceutical Industry (IPI), estimated at US$ 9 bn, has grown at a CAGR of 7%It is ranked 4th in volume terms and 11th in value terms globally. India’s share in the global pharmaceutical market is less than 2% in value terms as drug prices in India are one of the lowest in the world.
By: bharatbook.com The playing field for the domestic pharmaceutical companies (http://www.bharatbook.com/ The changing dynamics of the global pharmaceutical industry especially that of the regulated markets like USA and Europe have presented a number of opportunities for IPI to capitalize on. Some of the major concerns facing the global pharmaceutical industry are higher healthcare costs, competition from generics, patent expiries of blockbuster drugs, drying R&D pipelines and increasing R&D costs. These translate into a significant growth opportunity for IPI in the form of exports of generics to regulated markets and contract manufacturing/ The recognition of product patent has provided global companies with better IPR protection and as a result has opened up a new segment for the IPI in Contract Research and Manufacturing Services (CRAMS). IPI is well-positioned to take advantage of this opportunity with world class manufacturing facilities adhering to various regulatory standards, large pool of skilled manpower and cheaper cost of production. The investment in R&D is also on the rise as it has become important for Indian companies to start innovating new drugs in order to ensure long term sustainable growth and remain competitive at the global level. Indian companies have invested in New Chemical Entity (NCE) research and are scouting for global partners for pursuing collaborative research. The availability of large patient base, skilled manpower and lower costs of carrying out clinical trials has made India a favourable destination for R&D outsourcing. It believes that in the near to medium term horizon, the growth of IPI would be driven by exports to regulated markets and CRAMS. Companies having strong presence in these segments are likely to benefit more as compared other companies. Executive Summary 1. The Global Pharmaceutical Market: An Overview 1.1 Market size & growth 1.2 Geographic distribution 1.3 Leading therapy classes and top selling drugs 1.4 Leading global pharmaceutical companies 2. The Indian Pharmaceutical Industry: An Overview 2.1 Market size & growth trends 2.2 Exports 2.3 Leading therapeutic segments 2.4 Top Indian pharmaceutical companies 3. Indian Pharmaceutical Industry: Structure & classification 3.1 Size 3.2 Products 3.3 Geographical presence 4. Indian Pharmaceutical Market: A Profile 4.1 Demographics & health indicators 4.2 Disease profile 4.3 Healthcare spend by Indians 5. Indian Pharmaceutical Industry: Regulatory Framework 5.1 Indian Patents Act 5.2 WTO & TRIPS 5.3 The Government’s Pharmaceutical policy 5.4 Pricing of drugs & DPCO 5.5 Quality control guidelines 6. Indian Pharmaceutical Industry Value Road 7. Business & R&D Strategies 7.1 Domestic formulations 7.2 Exports to Semi/Non regulated markets 7.3 Contract research & manufacturing services (CRAMS) 7.4 Exports to Regulated markets: The generics opportunity 7.5 R&D strategies 8. Strategic Mapping of Indian Pharmaceutical Companies 9. Company Overview 9.1 Ranbaxy Ltd. 9.2 Cipla Ltd. 9.3 Dr. Reddy’s Laboratories Ltd. 9.4 Nicholas Piramal India Ltd. 9.5 Biocon Ltd. 9.6 Cadila Healthcare Ltd. 9.7 Matrix Laboratories Ltd. 9.8 Lupin Ltd. 9.9 Glenmark Pharmaceuticals Ltd. 9.10 Sun Pharamceutical Industries Ltd. Glossary of terms] List of Tables Table 1.1 Leading therapy classes of global pharmaceutical market Table 1.2 World’s top selling drugs Table 1.3 Global top-10 pharma companies Table 1.4 Patent expiry schedule of major blockbuster drugs in US 5-6 Table 2.1 India’s leading pharmaceutical companies Table 3.1 Number of companies & their size Table 4.1 Selected Population Indicators Table 4.2 Age-wise distribution of population of India Table 7.1 Top-10 domestic formulations companies Table 7.2 In-licensing deals by Indian pharma companies Table 7.3 Contract manufacturing deals by Indian pharma companies Table 7.4 Contract Research Organisations (CRO) in India Table 7.5 Leading drugs that have went off-patent during 2006 Table 7.6 ANDA filings and approvals by Indian pharma companies Table 7.7 R&D spends by Indian pharma companies as % of turnover Table 7.8 IPI’s NCE Pipeline Table 7.9 Out-licensing deals struck by Indian pharma companies Table 7.10 ANDA productivity on Indian & global generic companies OR Contact us at Bharat Book Bureau 207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India. Phone : +91 22 2757 8668 / 2757 9438 Fax : +91 22 2757 9131 E-mail : info@bharatbook.com Website : www.bharatbook.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|